To include your compound in the COVID-19 Resource Center, submit it here.

Tenaya to deploy $92M series B to develop heart disease platforms in parallel

With three platforms for heart disease, Tenaya sought patient investors to see them all forward

For its $92 million series B round, Tenaya sought a syndicate willing to invest enough that the company could advance heart disease programs from multiple modalities toward the clinic simultaneously.

The company's regenerative medicine and gene therapy programs could enter first-in-human studies as soon as late 2021, CEO Faraz Ali

Read the full 490 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers